CSIMarket
 
Foghorn Therapeutics Inc   (NASDAQ: FHTX)
Other Ticker:  
 
 
Price: $5.5200 $0.15 2.793%
Day's High: $5.72 Week Perf: 33.98 %
Day's Low: $ 5.32 30 Day Perf: 26.32 %
Volume (M): 126 52 Wk High: $ 10.25
Volume (M$): $ 695 52 Wk Avg: $6.51
Open: $5.32 52 Wk Low: $3.86



 Market Capitalization (Millions $) 346
 Shares Outstanding (Millions) 63
 Employees 49
 Revenues (TTM) (Millions $) 26
 Net Income (TTM) (Millions $) -91
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 0

Foghorn Therapeutics Inc
Foghorn Therapeutics Inc is a biotechnology company that focuses on developing precision medicines for patients with diseases caused by gene dysregulation. The company utilizes its proprietary Gene Traffic Control platform to gain insights into the role of chromatin regulation in gene expression and identify potential therapeutic targets. By targeting the complex mechanisms that control gene expression, Foghorn aims to develop innovative and transformative therapies for various diseases, including cancer and neurodegenerative disorders. The company is committed to advancing the understanding of gene regulation and translating their findings into novel treatments that have the potential to improve patient outcomes.


   Company Address: 500 Technology Square, Ste 700 Cambridge 2139 MA
   Company Phone Number: 586-3100   Stock Exchange / Ticker: NASDAQ FHTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        1.77% 
ARVN   -6.02%    
BPMC   -5.53%    
RYTM   -3.95%    
SUPN        0.36% 
YMAB   -3.89%    
• View Complete Report
   



Management Announcement

?Foghorn Therapeutics: Navigating Challenges and Opportunities in Precision Oncology?

Published Mon, Dec 16 2024 12:00 PM UTC

In an ever-evolving landscape of biopharmaceutical innovation, Foghorn Therapeutics Inc. stands at a critical juncture, showcasing both the promise and peril inherent in the quest for novel cancer treatments. The company recently provided an update on its clinical development programs, specifically relating to its candidate FHD-286, a treatment currently under investigation ...

Clinical Study

Advancements in Targeted Oncology Foghorn Therapeutics First-in-Class Oral SMARCA2 Inhibitor FHD-909 Doses First Pat...

Published Thu, Oct 10 2024 11:00 AM UTC

In a notable development for precision oncology, Foghorn Therapeutics Inc. has announced that the first patient has been dosed with their innovative oral therapeutic agent, FHD-909, during a Phase 1 clinical trial. This first-in-class SMARCA2 selective inhibitor is aimed at addressing solid tumors characterized by mutations in the SMARCA4 gene, with a primary focus on non-sm...

Stocks on the Move

Foghorn Therapeutics Inc Faces Market Performance Challenge Amidst Industry Growth

Published Fri, Jul 12 2024 5:44 PM UTC

In recent weeks, it appears that Foghorn Therapeutics Inc s shares have been trailing the performance of the entire market. This article aims to analyze this trend by interpreting relevant articles and shedding light on the company s recent developments and financial performance. Interpretations:1. HubSpot stock sinks as Alphabet reportedly sours on acquisition:According to...

Stock Market Announcement

Foghorn Therapeutics Secures $110 Million to Accelerate Pipeline Advancements and Unlock Clinical Value

Published Wed, May 22 2024 10:21 PM UTC



In a recent press release, Foghorn Therapeutics announced that it successfully raised approximately $110 million through a registered direct offering. This significant funding will fuel the company s ambitious plans to advance their pipeline and strengthen their platform. The article will provide an overview of the press release, discuss its implications for the co...

Shares

Foghorn Therapeutics Inc, a biotechnology company based in Cambridge, Massachusetts, recently made an announcement regarding the pricing of their registered direct offering of common stock and pre-funded warrants The offering includes 12,743,039 shares of common stock priced at $551 per share, alongside pre-funded warrants to purchase up to 7,220,794 shares of common stock at a price of $55099 per pre-funded warrant The offering is expected to close on or around May 22, 2024, subject to customary closing conditions It is noteworthy that all the shares of common stock to be sold in this offering are offered by Foghorn itself

Published Mon, May 20 2024 11:58 AM UTC

Foghorn Therapeutics Inc, a biotechnology company based in Cambridge, Massachusetts, recently made an announcement regarding the pricing of their registered direct offering of common stock and pre-funded warrants. The offering includes 12,743,039 shares of common stock priced at $5.51 per share, alongside pre-funded warrants to purchase up to 7,220,794 shares of common stock...







Foghorn Therapeutics Inc's Segments

  Foghorn Therapeutics Inc Outlook

On March 7 2024 the Foghorn Therapeutics Inc provided following guidance

Foghorn Therapeutics Inc. has release...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com